CW069
CAS: 1594094-64-0
Rif. 3D-UNC09464
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione | ||
100mg | Fuori produzione |
Informazioni sul prodotto
CW069 is a pegylated pharmaceutical preparation that has been found to have anti-cancer properties. CW069 has been shown to inhibit the activity of the ubiquitin-proteasome system, which is involved in the degradation of proteins. The drug also inhibits cell division by preventing the assembly of microtubules and disrupting mitosis. CW069 has been shown to be effective against chronic myelogenous leukemia and breast cancer cells, as well as other types of cancer. CW069 may be useful in treating autoimmune diseases such as arthritis or multiple sclerosis because it blocks the inflammatory response by inhibiting neutrophil migration, chemotaxis, and phagocytosis.